Fresenius Medical Care trims outlook. Fresenius Medical Care stock loses 2.38 percent

Published on 10/08/2026 at 12:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter operating income rose 23 percent. Fresenius Medical Care stock costs EUR 36.58 on October 8, 2026 after EUR 37.47.

Makroaufnahme feiner Hohlfaser-Membranstränge eines Dialysators mit Wassertropfen — Makroaufnahme zeigt feine Dialysemembran-Fasern mit Wassertropfen, Sinnbild für Fresenius Medical Care AG DE0005785802 in Detailschärfe, Illustration mit AI erstellt.

Fresenius Medical Care (DE0005785802) stock was at EUR 36.58 at Lang & Schwarz on October 8, 2026 at 12:20 p.m. CEST, down 2.38 percent versus the prior close of EUR 37.47. On October 7, 2026, TradingView carried a Zacks report saying management had reduced Value-Based Care revenue guidance for 2026 to EUR 150-200 million from EUR 300 million.

Value-Based Care faces a lower target

The revised range is a concrete counterweight to the broader efficiency story. Value-Based Care revenue increased 9 percent organically at constant currency in the second quarter of 2026, while operating income improved to EUR 18 million from a EUR 9 million loss a year earlier, according to TradingView.

The guidance cut matters because the segment is becoming more profitable while its expected revenue contribution is being reset. For investors, that creates a sharper distinction between margin improvement and top-line scale.

Profit growth offsets operating pressure

Fresenius Medical Care delivered EUR 67 million of sustainable savings in the second quarter of 2026, and group operating income rose 23 percent at constant currency, with operating margin expanding 180 basis points, according to TradingView. Care Delivery operating income increased 45 percent organically in the same period, although US same-market treatment growth declined 0.9 percent.

The contrast is important: cost savings and reimbursement effects are supporting earnings, while treatment volumes and referral capture remain operational pressure points.

Leadership change adds a new test

Fresenius Medical Care announced on October 7, 2026 that Shervin J. Korangy will become CEO and chair of the Management Board on October 12, 2026, succeeding Helen Giza. The company said the FME25+ program had reduced its cost base by EUR 1.2 billion, setting a high execution benchmark for the next phase.

The investor question is whether the incoming leadership can convert that efficiency base into durable growth while the Value-Based Care outlook is lower and treatment volumes remain uneven.

Stock trades below its prior close

At Lang & Schwarz, Fresenius Medical Care stock was trading at EUR 36.58 on October 8, 2026 at 12:20 p.m. CEST, down 2.38 percent versus the prior close of EUR 37.47. The company is scheduled to report third-quarter 2026 results on November 3, 2026, according to its investor-relations page. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.